Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.
The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.
Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.
Price: 8.60, Change: +0.77, Percent Change: +9.77
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。